Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ELAINEIII
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- NCT05696626 ↗
- Recruiting
- LeonaBio
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- Lasofoxifene in combination with abemaciclib; Fulvestrant in combination with abemaciclib
- Arms
- Treatment · Experimental
- Reference Therapy · Active comparator
- Enrollment
- 600 (estimated)
- Primary outcomes
- Progression free survival (PFS)
- Sponsor
- LeonaBio
- Start
- Oct 31, 2023
- Primary completion
- Apr 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05696626 · updated Jun 22, 2026
Publications
linked from the registry- Goetz MP, Wander SA, Bachelot T, de Nonneville A, Gal-Yam EN, Sammons SL, Shen S, Twelves C, Boruta G, Portman DJ, Damodaran S. ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1-mutated, metastatic breast cancer. Future Oncol. 2025 May;21(11):1317-1324. doi: 10.1080/14796694.2025.2481825. Epub 2025 Apr 13. PubMed 40222048